Back to Careers

CEO Dr. Hanadie Yousef shares an Industry Update on JUV-161 and our plans to initiate Phase 1 studies this year at the 2025 International MDF Conference in  Indianapolis

Back to Careers

Our CEO, Hanadie Yousef, discussed Juvena’s growing and advancing pipeline of tissue restorative biologics for myopathies and obesity with Miranda Schmalfuhs from Pharmaceutical Executive

Back to Careers

Our Senior Director of Discovery and Platform, Dr. Thach Mai, attended Google Cloud Next ‘25 to explore cutting-edge AI and cloud innovations transforming drug discovery and precision therapeutics

Back to Careers

Dr. Hanadie Yousef gave a talk on “Building a Pipeline with Purpose: Turning a Platform into Strategic Asset Value” as an invited speaker at Fierce Pharma Engage BD&L Summit in San Diego

Back to Careers

Healthspan Capital highlights Juvena Therapeutics in its LongBio Report comprehensively profiling the leading companies in longevity biotechnology

Back to Careers

Juvena was honored to present at the IGF and Insulin System in Physiology and Disease Gordon Research Conference! Our CSO and Co-Founder, Jeremy O’Connell, had a great opportunity to present our JUV-161 program and engage in insightful discussions on the latest advancements in IGF biology

Back to Careers

Our SVP of Drug Development, Dr. Banmeet Anand, presented Juvena’s clinical stage metabolic program (JUV-161) that enhances muscle regeneration for the treatment of sarcopenia and myotonic dystrophy type 1 (DM1) at the International Conference of Frailty and Sarcopenia in Toulouse, France

Back to Careers

Our CSO and Co-founder, Jeremy O’Connell, presented Juvena’s metabolic program discoveries at the UCLA Symposium on Anti-Obesity Treatments.

Back to Careers

Our CEO Dr. Hanadie Yousef presented updates on Juvena’s platform and advancing pipeline of tissue restorative biologics for muscle and metabolic diseases at Biocom California’s Global Life Science Partnering and Investor Conference